Table 3.
Efficacy and Safety in CPT A versus CPT B/C Patients According to RBV Protocol
| Variable | CPT A without RBV n° 56 | CPT B/C without RBV n° 14 | p-value |
|---|---|---|---|
| HCV RNA SVR12 | 50 (89.3) | 11 (78.6) | 0.2 |
| Anemia | 2 (3.6) | 1 (7.1) | 0.4 |
| Fatigue | 5 (8.9) | 5 (35.7) | 0.02 |
| Headache | 0 | 0 | NS |
| Diarrhea | 0 | 0 | NS |
| SAE | 0 | 1 (7.1) | 0.2 |
| CPT A flat RBV n° 78 | CPT B/C flat RBV n° 9 | ||
| HCV RNA SVR12 | 78 (100) | 7 (77.8) | 0.01 |
| Anemia | 14 (17.9) | 3 (33.3) | 0.2 |
| Fatigue | 17 (21.8) | 2 (22.2) | 0.6 |
| Headache | 5 (6.4) | 0 | 0.5 |
| Diarrhea | 2 (2.6) | 0 | 0.8 |
| SAE | 1 (1.3) | 1 (11.1) | 0.08 |
| CPT A weight dose RBV n° 73 | CPT B/C weight dose RBV n° 5 | ||
| HCV RNA SVR12 | 71 (98) | 5 (100) | 0.8 |
| Anemia | 26 (35.6) | 4 (80) | 0.05 |
| Fatigue | 25 (34.2) | 3 (60) | 0.2 |
| Headache | 5 (6.8) | 1 (20) | 0.3 |
| Diarrhea | 2 (2.7) | 0 | 0.8 |
| SAE | 0 | 0 | NS |
Data are presented as number (%).
CPT, Child-Pugh-Turcotte; RBV, ribavirin; HCV, hepatitis C virus; SAE, severe adverse event; NS, significant.